DE3769812D1 - Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion. - Google Patents
Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion.Info
- Publication number
- DE3769812D1 DE3769812D1 DE8787301403T DE3769812T DE3769812D1 DE 3769812 D1 DE3769812 D1 DE 3769812D1 DE 8787301403 T DE8787301403 T DE 8787301403T DE 3769812 T DE3769812 T DE 3769812T DE 3769812 D1 DE3769812 D1 DE 3769812D1
- Authority
- DE
- Germany
- Prior art keywords
- phosphordiesteras
- tenary
- nucleotid
- analogs
- secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/830,997 US4753945A (en) | 1986-02-19 | 1986-02-19 | Stimulation of tear secretion with phosphodiesterase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE3769812D1 true DE3769812D1 (de) | 1991-06-13 |
Family
ID=25258069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE8787301403T Expired - Fee Related DE3769812D1 (de) | 1986-02-19 | 1987-02-18 | Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion. |
Country Status (4)
Country | Link |
---|---|
US (1) | US4753945A (de) |
EP (1) | EP0234854B1 (de) |
JP (1) | JPH0788311B2 (de) |
DE (1) | DE3769812D1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4938965A (en) * | 1987-07-22 | 1990-07-03 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government | Ocular delivery of prophylactic agents |
US4975428A (en) * | 1988-05-31 | 1990-12-04 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
EP0406210B1 (de) * | 1989-06-29 | 1995-09-27 | Washington University | Ophthalmikum |
CA2052193A1 (en) * | 1990-09-28 | 1992-03-29 | Norio Takasugi | Topical powder composition containing cyclic amp derivative |
US5545617A (en) * | 1993-11-12 | 1996-08-13 | The Schepens Eye Research Institute, Inc. | Therapeutic regulation of abnormal conjunctival goblet cell mucous secretion |
US5900407A (en) * | 1997-02-06 | 1999-05-04 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with uridine triphosphates and related compounds |
US6921755B2 (en) * | 1998-02-06 | 2005-07-26 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with purinergic receptor agonists |
US6696425B2 (en) * | 1997-02-06 | 2004-02-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with purinergic receptor agonists |
US6462080B1 (en) | 1998-12-24 | 2002-10-08 | Alcon Manufacturing, Ltd. | Prostaglandin E receptor agonists for treatment of dry eye |
AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
JP4591728B2 (ja) * | 1998-12-28 | 2010-12-01 | 大正製薬株式会社 | 眼精疲労改善用点眼剤 |
US7544772B2 (en) | 2001-06-26 | 2009-06-09 | Biomarck Pharmaceuticals, Ltd. | Methods for regulating inflammatory mediators and peptides useful therein |
JP5620037B2 (ja) * | 1999-02-24 | 2014-11-05 | ノース・キャロライナ・ステイト・ユニヴァーシティ | 粘液分泌を変化させる方法および組成物 |
US8501911B2 (en) * | 1999-02-24 | 2013-08-06 | Biomarck Pharmaceuticals, Ltd | Methods of reducing inflammation and mucus hypersecretion |
MXPA01008547A (es) | 1999-02-26 | 2003-06-06 | Inspire Pharmaceuticals Inc | Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos. |
AU1475701A (en) | 1999-11-09 | 2001-06-06 | Alcon Inc. | Lipoxin A4 and its analogs for the treatment of dry eye |
AU1101301A (en) | 1999-11-09 | 2001-06-06 | Alcon Universal Limited | 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use |
US6326499B1 (en) | 1999-11-09 | 2001-12-04 | Alcon Universal Ltd. | Omega chain modified 15-hydroxyeicosatetraenoic acid derivatives and methods of their use for the treatment of dry eye |
BR0015416A (pt) | 1999-11-09 | 2002-07-16 | Alcon Inc | Composições contendo derivados do ácido hidroxieicosa tetraenóico e métodos de uso no tratamento de distúrbios de olhos secos |
CA2386333A1 (en) | 1999-11-09 | 2001-05-17 | Alcon, Inc. | 3-heteroatom substituted and two carbon homologs 15-hete and methods of use |
PT1228026E (pt) | 1999-11-09 | 2004-04-30 | Alcon Inc | Compostos relacionados com o acido 15-hidroxieicosatetraenoico |
US6552084B2 (en) | 1999-11-09 | 2003-04-22 | Alcon Universal Ltd. | Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
WO2001034129A2 (en) | 1999-11-09 | 2001-05-17 | Alcon Universal Ltd. | Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use |
US6803385B2 (en) | 1999-11-09 | 2004-10-12 | Alcon, Inc. | Hydroxyeicosatetraenoic acid analogs and methods of their use in treating dry eye disorders |
US6320062B1 (en) | 1999-11-09 | 2001-11-20 | Alcon Universal Ltd. | 15-hydroxyeicosatetraenoic acid analogs with enhanced metabolic stability and methods of their use in treating dry eye disorders |
CA2388044A1 (en) | 1999-11-09 | 2001-05-17 | Alcon, Inc. | Hydroxyeicosatetraenoate salts, compositions and methods of use in treating dry eye disorders |
CA2388030A1 (en) | 1999-11-09 | 2001-05-17 | Alcon, Inc. | Benzenoid derivatives of 15-hydroxyeicosatetraenoic acid and methods of their use in treating dry eye disorders |
AU1226001A (en) | 1999-11-09 | 2001-06-06 | Alcon Universal Limited | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives |
US6458854B2 (en) | 1999-11-09 | 2002-10-01 | Alcon Universal Ltd. | Phospholipids of hydroxyeicosatetraenoic acid-like derivatives and methods of use |
AU1731101A (en) * | 1999-12-07 | 2001-06-18 | Rohto Pharmaceutical Co., Ltd. | Ophthalmic compositions |
AU2603301A (en) | 1999-12-22 | 2001-07-03 | Alcon Universal Limited | 6-keto prostaglandin F1alpha and analogs for treating dry eye |
US7919469B2 (en) * | 2000-02-24 | 2011-04-05 | North Carolina State University | Methods and compositions for altering mucus secretion |
US7265088B1 (en) | 2000-02-24 | 2007-09-04 | North Carolina State University | Method and compositions for altering mucus secretion |
US6277855B1 (en) | 2000-04-21 | 2001-08-21 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with nicotinic acetylcholine receptor agonists |
PT1304991E (pt) * | 2000-07-12 | 2014-12-09 | Rogue Valley Natural Springs Inc | Método e kit para a hidratação da superfície do olho |
US7524511B1 (en) | 2000-07-12 | 2009-04-28 | Rogue Valley Natural Springs, Inc. | Method and kit for moisturizing the surface of the eye |
WO2002034258A1 (en) | 2000-10-23 | 2002-05-02 | Alcon, Inc. | Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
WO2003030894A1 (en) * | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
CA2462272A1 (en) * | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
WO2003030892A1 (en) * | 2001-10-11 | 2003-04-17 | Alcon, Inc. | Methods for treating dry eye |
JP4554931B2 (ja) | 2001-12-20 | 2010-09-29 | メルク セローノ ソシエテ アノニム | プロスタグランジン調節物質としてのピロリジン誘導体 |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
AU2003232828B2 (en) * | 2002-05-28 | 2010-06-24 | Takeda Gmbh | Topically applicable pharmaceutical preparation |
US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
AU2003278727A1 (en) * | 2002-09-20 | 2004-04-08 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
WO2004060274A2 (en) * | 2002-12-20 | 2004-07-22 | Alcon, Inc. | Treatment of dry eye by restoring 15-lipoxygenase activity to ocular surface cells |
ES2335498T3 (es) | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
US7488713B2 (en) | 2004-03-18 | 2009-02-10 | University Of South Florida | Cancer treatment using C-type natriuretic peptides |
US20050074497A1 (en) * | 2003-04-09 | 2005-04-07 | Schultz Clyde L. | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
US9216106B2 (en) * | 2003-04-09 | 2015-12-22 | Directcontact Llc | Device and method for the delivery of drugs for the treatment of posterior segment disease |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20050208102A1 (en) * | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
AU2005227870A1 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
US8759317B2 (en) | 2004-03-18 | 2014-06-24 | University Of South Florida | Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP) |
MX2007008744A (es) | 2005-01-20 | 2008-03-10 | Biomarck Pharmaceuticals Ltd | Inhibidores de hipersecrecion de mucina con base en la estructura de mans ymetodos de uso. |
AU2006224619B2 (en) * | 2005-03-16 | 2012-06-07 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
US7247623B2 (en) * | 2005-08-19 | 2007-07-24 | Inspire Pharmaceuticals, Inc. | Method of treating dry eye disease with non-drying antihistamines |
US20070207116A1 (en) * | 2006-03-01 | 2007-09-06 | Brown David C | Antioxidant compositions for the eye |
WO2007130672A2 (en) * | 2006-05-05 | 2007-11-15 | University Of South Florida | Urodilatin cancer treatment |
RU2423376C2 (ru) * | 2006-07-26 | 2011-07-10 | Байомарк Фармасьютикалз, Лтд. | Способы ослабления высвобождения медиаторов воспаления и пептиды, применяемые для этой цели |
US7825092B2 (en) * | 2006-08-08 | 2010-11-02 | University Of South Florida | Dendroaspis natriuretic peptide for treatment of cancer |
US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
US20150031712A1 (en) | 2013-03-12 | 2015-01-29 | Moshe Rogosnitzky | Therapeutic Compositions Containing Dipyridamole and Treatment Packs Including Such Compositions and Methods for Producing Same |
DE102014203152A1 (de) * | 2014-02-21 | 2015-08-27 | Ursapharm Arzneimittel Gmbh | Mikro- oder Nanoemulsion zur ophthalmologischen Anwendung |
AU2016298794A1 (en) | 2015-06-08 | 2018-02-01 | O.D. Ocular Discovery Ltd. | Therapeutic compositions containing dipyridamole, treatment packs and kits including such compositions, and methods for producing same |
CN112513303B (zh) | 2018-11-09 | 2022-05-24 | 日铁不锈钢株式会社 | 铁素体系不锈钢板 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE897492C (de) * | 1943-11-02 | 1953-11-23 | Ruhrchemie Ag | Automatische Gas-Dauerprobenahme-Apparatur mit regelbarer Dosierung |
NL247008A (de) * | 1959-07-22 | 1900-01-01 | ||
FR2358155A1 (fr) * | 1976-07-15 | 1978-02-10 | Lapinet Eugene | Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses |
GB1561037A (en) * | 1976-07-15 | 1980-02-13 | Cehovic G | Composition for the treatment and prevention of skin eye and mucosal inflammation |
US4208408A (en) * | 1978-03-06 | 1980-06-17 | Sandoz, Inc. | Substituted 1-oxa-4-aza-2,6-disilacyclohexanes |
CA1165241A (en) * | 1980-05-06 | 1984-04-10 | Bristol-Myers Squibb Company | Sustained release theophylline tablet having reduced bulk |
IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
US4559343A (en) * | 1982-09-07 | 1985-12-17 | Alcon Laboratories, Inc. | Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therapeutic agents |
JPH0729927B2 (ja) * | 1983-04-09 | 1995-04-05 | 日研化学株式会社 | テオフィリン徐放性製剤 |
US4478822A (en) * | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4717713A (en) * | 1983-10-31 | 1988-01-05 | Research Corporation | Controlled release liquid pharmaceutical |
IE58246B1 (en) * | 1984-12-21 | 1993-08-11 | Byk Gulden Lomberg Chem Fab | Theophylline sustained release formulation |
-
1986
- 1986-02-19 US US06/830,997 patent/US4753945A/en not_active Expired - Lifetime
-
1987
- 1987-02-18 JP JP62033582A patent/JPH0788311B2/ja not_active Expired - Fee Related
- 1987-02-18 EP EP87301403A patent/EP0234854B1/de not_active Expired - Lifetime
- 1987-02-18 DE DE8787301403T patent/DE3769812D1/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0234854B1 (de) | 1991-05-08 |
US4753945A (en) | 1988-06-28 |
EP0234854A3 (en) | 1987-11-19 |
JPH0788311B2 (ja) | 1995-09-27 |
EP0234854A2 (de) | 1987-09-02 |
JPS62246524A (ja) | 1987-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE3769812D1 (de) | Verwendung von phosphordiesteraseinhibitoren und cyclischen nukleotidanalogen zur herstellung eines arzneimittels zur stimulierung der traenensekretion. | |
DE3585607D1 (de) | Verwendung von paroxetine zur herstellung eines arzneimittel zur behandlung von obesitaet. | |
DE3485075D1 (de) | Pharmazeutische zubereitung zur heilung der erkrankungen der zahnwurzelhaut und verfahren zu deren herstellung. | |
ATA68386A (de) | Verwendung von 3'-azido-3'-desoxythymidin oder eines pharmazeutisch annehmbaren derivats hievon zur herstellung von medikamenten | |
ATE176873T1 (de) | Verfahren zur herstellung von applikatoren zur transdermalen verabreichung von medikamenten | |
ATE126433T1 (de) | Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen. | |
DE3650700D1 (de) | Verwendung eines Massbandes zur Direktbestimmung von Parametern für die physikalische Therapie und physiologischer Grössen | |
DE3888177D1 (de) | Schnellauflösbare arzneimitteldosierungseinheit sowie verfahren zur herstellung. | |
PT78940A (de) | Neue insulin-derivate verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus | |
ATA243992A (de) | Verfahren zur herstellung von zur selektiven senkung des blutlipoidspiegels geeigneten arzneimittelpräparaten | |
DE3785740D1 (de) | Verwendung von carboxamid-verbindungen zur herstellung eines arzneimittels zur behandlung der hyperlipaemie. | |
PT83186A (de) | Verfahren zur herstellung einer stabilen modifikation von torasemid sowie arzneimittel enthaltend torasemid | |
DE68924714D1 (de) | Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen. | |
DE3583220D1 (de) | Verwendung von dipeptidderivaten fuer die herstellung von arzneimitteln zur behandlung von an amyotropher lateralsklerose erkrankten. | |
PT81531A (de) | Verfahren zur herstellung von isosilybinfreiem silibinin und araneimittel enthaltend silibinina | |
PT81829A (de) | Traegermatrix zur aufnahme von katalytisch wirkenden verbindungen und verfahren zur herstellung der traegermatrix | |
ATA232687A (de) | Zahnpflegemittel, sowie verfahren zur herstellung des zahnpflegemittels | |
DE3768150D1 (de) | Verwendung eines 1,3-oxazolidin-2-on-derivates zur herstellung eines arzneimittels zur behandlung von ischaemie. | |
DE3675115D1 (de) | Verwendung von verbindungen zur herstellung eines medikaments fuer die behandlung von grauem star. | |
DE68905657D1 (de) | Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen. | |
DE3686097D1 (de) | Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht. | |
ATA327685A (de) | Verfahren zur herstellung eines neuen lymphokins (lk 2) sowie verwendung von lk 2 zur herstellung eines pharmazeutischen praeparates | |
DE3873210D1 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
DE3873188D1 (de) | Verwendung von nigerizin zur herstellung eines mittels zur behandlung von virus-erkrankungen. | |
DE3483944D1 (de) | Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |